
crofabiotech

The first Latin America startup with a genetically edited piglet born

GENETICALLY EDITED ORGANS
SUITABLE FOR HUMAN TRANSPLANTATION

Since 2022. Buenos Aires, Argentina



CAPITAL RAISED TODAY

crofabiotech

Now backed to advance a solution to the global organ shortage.

JUNE 2026

SEED ROUND CLOSED

U$D 6.7M

LONGEVITY

North American Longevity Focused Fund

The only Argentina-based deep-tech startup to receive this level of funding at the Seed stage.

PRE-SEED ROUND CLOSED

JULY 2023

U$D 700 K

avalian
COBERTURA MÉDICA

Argentine Private Healthcare Group

An investment 3× larger than the average Pre-Seed investment in deep tech in Argentina.

GLOBAL PROBLEM

crofabiotech

"Medicine faces a structural limit:
an inefficient, slow, and non-scalable model."

Each year, more than **4 millon people worldwide** need a trasplant.



80%
ARE KIDNEYS → LESS THAN 5%
RECEIVE ONE

MARKET
Xenotrasplants, Dyalisis → 2031 | U$D 180B

PRODUCT

Science makes it possible to create a real, scalable, and accessible solution.



PLATFORM crofa biotech

1

Gene Editing

Modify key genes to reduce biological barriers.
CRISPR/Cas9 gene editing.

2

Replicating the Modification

Transfer the genetic information to generate embryos with the desired characteristics.
Nuclear transfer cloning.

3

Developing & Monitoring Animals

Apply reproductive biotechnology to enable birth and study their development.

¿WHAT THIS TECHNOLOGY ENABLES?

Advancing the development organs with the potential for human compatibility.

OUR PLATFORM ALSO ENABLES:

- MODELING OF TISSUES & ANIMALS FOR RESEARCH AND THERAPY DEVELOPMENT
- ON-DEMAND GENETIC EDITING
- SHORTER TIMELINES AND GREATER PRECISION IN R&D OF NEW THERAPIES AND DRUGS.

PRODUCT

crofabiotech

We are already doing it

CrofaPig®

What comes next technically?
Organs designed for improved compatibility with the human body

Most Important Scientific Milestone

The birth and survival of the first litter of piglets with 100% genetically edited organs using our proprietary technology.


MAY 2026
First births

JULY, AUGUST & SEPTEMBER 2026

ADDITIONAL BIRTHS

From Science Fiction to a Tangible Reality

A growing regulatory framework and real-world evidence of advances around the world



UNITED STATES

- February 2025
- The FDA approved the first clinical trial
- Patients are surviving after receiving genetically engineered organs in the United States and China

CHINA

- Approved its first clinical trial

WORLD HEALTH ORGANIZATION (WHO)

- Global regulatory frameworks under development

ARGENTINA

- Regulatory framework under development

crofabiotech

An institutional and innovation ecosystem with scientific, regulatory, and productive capacity of global impact.

Pigs with certified sanitary status, enabling DPF generation.

Pioneer country in biotechnology regulation: CONABIA, Bioeconomy framework, Modern Biotechnology Law.

Second global clinical trial of xenotransplantation in 2011 (porcine islets).

Strategic Hub for LATAM.



Top 10 worldwide in number of biotech companies (+340 companies).

Highest researcher density per capita in LATAM

Argentine Chamber of Biotechnology with **300+ biotech companies** (Crofabiotech is a member).

Fiscal incentives and solid legal framework: **Knowledge Economy Law, Argentina Innovadora 2030 Plan.**

Consolidating and Expanding Our In-House Capabilities and Strategic Partnerships

crofabiotech

2026

SCIENTIFIC

- Next-generation gene-edited pigs

FINANCIAL

- USD 6M seed round secured from U.S Longevity Venture Fund (LVF).

REGULATORY

- Preclinical phase underway.
- Advancing the global regulatory framework. Invited by the World Health Organization
  (GLOBAL REGULATORY FRAMEWORK)
- Dialogue with Argentine regulatory authorities.

BUSINESS

- New strategic partnerships.
- Biotechnology services for corporate clients.
- Expanded CROFA Biotech team.

2027

IN-HOUSE CAPABILITIES

- Upcoming proprietary DPF (Designated Pathogen-Free) facility in Argentina.
- First human xenotransplant estimated.

The facility will enable us to breed and monitor animals under controlled sanitary conditions, reduce external dependencies and improve reproducibility.

STRATEGIC ALLIANCES

crofabiotech

Long-Term Partnerships Built Across the Entire Ecosystem

INSTITUTIONAL ENDORSEMENTS & STRATEGIC VALIDATION

SCIENTIFIC & ACADEMIC INSTITUTIONS

UBA Universidad de Buenos Aires

UNLPam Universidad Nacional de La Pampa

UNSAM

PUBLIC & PRIVATE HEALTHCARE INSTITUTIONS

ncucai

ITAC Instituto de Trasplante y Alta Complejidad

CEMIC

FUNDACIÓN FAVALORO

INTERNATIONAL ORGANIZATIONS

World Health Organization

HEALTH-FOCUSED INVESTMENT FUNDS

avalian

LONGEVITY

LETTERS OF SUPPORT

CELLARION LIFE BEYOND LIMITS

Eledon Pharmaceuticals

ELEMENTAL TRANSLATIONAL RESEARCH

crofabiotech



We monetize through three complementary and strategically integrated channels, enabling progressive scaling from LATAM

MODEL PLANT IN ARGENTINA

HIGH-COMPLEXITY BIOTECH PRODUCTS

- Genetically edited organs and tissuesL
- CLIENTS:
  Direct sales to laboratories, biotech companies, CROs, clinics, and institutes

SPECIALIZED BIOTECHNOLOGICAL SERVICES

- Custom gene editing
  Cellular and animal models for R&D
  High-value recurring revenues per project or subscription

TECHNOLOGY LICENSING (TECH TRANSFER)

- Technology transfer, know-how, comprehensive support, and updates
- REVENUES:

Upfront + Payments (technical/regulatory). *Milestones payments* + Royalties from generated organs

GLOBAL SCALABILITY WITHOUT REPLICATING INFRASTRUCTURE

Services we are able to offer with our current capabilities (B2B)

- Gene editing of stem cells for customized studies and developments
- Tissue/animal modeling for research and development
- Scientific consulting + Technology transfer

TEAM


A founding team with decades of real-world experience



CEO

Adrián Mutto
BsC, MsC, PhD

Global expert in genetic editing and animal cloning, with 25+ years leading biotechnological centers



CSO

Adrián Abalovich
BsC, MsC PhD

Pioneer in xenotransplantation, with 30+ years of medical experience



CFO

Mariela Balbo
BsC, MsC

25+ years in business development and innovation.



INTERNATIONAL ADVISORY BOARD

Marcelo Grabois
Intellectual property expert (ITERA)

Gustavo Garrido
Legal support: Garrido & Asociados Law Firm

Muhammad M Mohiudin
Xenotrasplantation Specialist

Daniel de Florian
Expert in artificial intelligence (CIAI)

We aim to consolidate our international expansion.

De-risked enough to believe in.

Early enough to shape the upside.

Mariela Balbo. CFO
+54 9 2214 85-5352
mariela.balbo@gmail.com

crofabiotech